Tierra Biosciences
- 14/03/2024
- Series A
- $11,400,000
Tierra Biosciences is a synthetic biology company that accelerates the pace of discovery and enables the next generation of bio-based materials. Tierra’s first product, the Tierra Protein Platform, couples high-throughput protein manufacturing with the simplicity of e-commerce to make ordering custom proteins easier than ever before. By lowering the traditional protein synthesis barrier, Tierra serves scientists looking to change the world with novel proteins. Led by a team of protein experts, this fast-growing company is transforming the way people discover, screen, and develop proteins for future bio-based products. For more information, visit tierrabiosciences.com.
- Industry Biotechnology Research
- Website https://www.tierrabiosciences.com/
- LinkedIn https://www.linkedin.com/company/tierrabiosciences/
Related People
Michael NemzekFounder
Executive leader with consistent, verifiable success in achieving rapid revenue and profit growth objectives within startups, public turnaround and rapid-change environments in life science and high-technology markets. Expertise in fast transformative strategy development and implementation, with several successful exits and several billion dollars in value creation for shareholders.
Areas of expertise include:
• P&L Management
• Strategic Planning
• Product Lifecycle Management
• Marketing Communication and Branding
• Marketing Management
• Digital Marketing Deployment
• Global Commercial Management (Sales, Service, Field Applications and Support)
• Corporate Turnaround
• Global Launch of Products
• Development of Key Opinion Leaders
• Partnership Management
• Talent Recruitment & Development
• Business Development
• Advanced Instrumentation, Liquid Handling, Automation, Reagents, Assay and Software Development
• Life Sciences, Genomics, NGS, DNA Sequencing, Drug Discovery, Cell Biology, Molecular Biology, Immunology, Proteomics, Bioinformatics and Microbiome Analysis
I have held senior executive leadership positions in public corporations including Affymetrix, Symyx Technologies and EG&G achieving highly successful growth. I have served in senior executive roles in start-ups that have become successful public companies by merger at multiples above market norms. These include Velocity11, acquired by Agilent Technologies, where I was Vice President of Marketing; Cellomics, Inc., acquired by Fisher Scientific, where I was Chief Business Officer; Tropix, Inc., acquired by Perkin Elmer - Applied Biosystems Division, where I was Vice President of Sales and Marketing; and Genosys Biotechnologies, Inc., acquired by Sigma Aldrich Corp., where I was Vice President of Sales and Marketing.